Spruce Biosciences Inc. (SPRB): Price and Financial Metrics
SPRB Price/Volume Stats
| Current price | $0.45 | 52-week high | $5.95 |
| Prev. close | $0.45 | 52-week low | $0.41 |
| Day low | $0.43 | Volume | 632,200 |
| Day high | $0.46 | Avg. volume | 739,212 |
| 50-day MA | $0.49 | Dividend yield | N/A |
| 200-day MA | $1.59 | Market Cap | 18.42M |
SPRB Stock Price Chart Interactive Chart >
Spruce Biosciences Inc. (SPRB) Company Bio
Spruce Biosciences, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on developing novel therapies for rare diseases affecting the endocrine system. The company was founded in 2014 and is headquartered in Daly City, CA.
Latest SPRB News From Around the Web
Below are the latest news stories about SPRUCE BIOSCIENCES INC that investors may wish to consider to help them evaluate SPRB as an investment opportunity.
Spruce Biosciences Reports Third Quarter 2023 Financial Results and Provides Corporate UpdatesSOUTH SAN FRANCISCO, Calif., November 13, 2023--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today reported financial results for the third quarter ended September 30, 2023 and provided corporate updates. |
Spruce Biosciences to Participate in the Jefferies London Healthcare ConferenceSOUTH SAN FRANCISCO, Calif., November 02, 2023--Spruce Biosciences to Participate in the Jefferies London Healthcare Conference |
Spruce Biosciences Completes Target Enrollment of CAHmelia-203 Study in Adult Classic Congenital Adrenal HyperplasiaSOUTH SAN FRANCISCO, Calif., October 18, 2023--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced completion of target enrollment of 72 patients and closure of screening in the CAHmelia-203 clinical trial evaluating tildacerfont for the treatment of adult classic congenital adrenal hyperplasia (CAH) and provided updated anticipat |
Spruce Biosciences to Participate in the H.C. Wainwright 25th Annual Global Investment ConferenceSOUTH SAN FRANCISCO, Calif., August 28, 2023--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, will present at the H.C. Wainwright 25th Annual Global Investment Conference on September 12, 2023, at 3:30 p.m. ET. |
Spruce Biosciences Reports Second Quarter 2023 Financial Results and Provides Corporate UpdatesSOUTH SAN FRANCISCO, Calif., August 14, 2023--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today reported financial results for the second quarter ended June 30, 2023 and provided corporate updates. |
SPRB Price Returns
| 1-mo | -2.79% |
| 3-mo | -12.20% |
| 6-mo | -38.36% |
| 1-year | -81.63% |
| 3-year | -93.11% |
| 5-year | N/A |
| YTD | -84.64% |
| 2023 | 166.99% |
| 2022 | -75.39% |
| 2021 | -81.65% |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...